Related Experiment Videos
Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial
Scandinavian Journal of Gastroenterology
|May 1, 1985
Summary
High-dose antacids and ranitidine effectively treat reflux esophagitis symptoms, outperforming placebo. Both treatments showed equal efficacy in this short-term study for gastroesophageal reflux disease.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Gastroesophageal reflux disease (GERD) presents with symptoms and endoscopic signs of esophagitis.
- Effective short-term management of GERD symptoms is crucial for patient well-being.
Purpose of the Study:
- To compare the efficacy of Novaluzid (a liquid antacid) with ranitidine and placebo in treating reflux esophagitis.
- To evaluate symptomatic and endoscopic outcomes in patients with GERD.
Main Methods:
- A randomized, three-period, double-dummy crossover trial involving 57 patients.
- Treatments included Novaluzid (10 ml TID), ranitidine (150 mg BID), and placebo over 6-week periods.
- Statistical analysis considered completers and patients with at least two treatment periods.
Main Results:
- Both ranitidine and Novaluzid significantly improved pain scores compared to placebo (p < 0.005).
- No significant differences were observed between ranitidine and Novaluzid.
- Neither active treatment showed superiority over placebo for regurgitation, dysphagia, histology, or endoscopic appearance (p > 0.05).
Conclusions:
- Ranitidine and high-dose antacids demonstrate equal effectiveness in the short-term treatment of reflux esophagitis.
- Both active treatments provide superior symptomatic relief compared to placebo for GERD.